Natera (NASDAQ:NTRA) Insider Sells $1,242,660.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $414.22, for a total transaction of $1,242,660.00. Following the transaction, the insider directly owned 106,914 shares of the company’s stock, valued at $44,285,917.08. This trade represents a 2.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Tuesday, September 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $320.73, for a total transaction of $962,190.00.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $263,094.90.

Natera Stock Performance

Shares of Natera stock opened at $410.35 on Monday. The business’s fifty day moving average price is $332.39 and its 200 day moving average price is $261.45. Natera, Inc. has a twelve month low of $160.59 and a twelve month high of $427.47. The stock has a market capitalization of $59.15 billion, a P/E ratio of -301.73 and a beta of 1.50.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm’s revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.74) earnings per share. As a group, sell-side analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NTRA. TD Cowen raised their price target on shares of Natera from $325.00 to $340.00 and gave the company a “buy” rating in a report on Friday, August 7th. Barclays reissued an “overweight” rating and issued a $340.00 price objective on shares of Natera in a research report on Friday, August 7th. BTIG Research raised their target price on shares of Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Stephens lifted their target price on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Finally, UBS Group upped their price target on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $341.55.

Institutional Trading of Natera

A number of hedge funds have recently made changes to their positions in NTRA. Polaris Financial Partners purchased a new position in shares of Natera in the third quarter valued at $114,000. Versant Capital Management Inc increased its stake in Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after buying an additional 36 shares during the period. Burkett Financial Services LLC acquired a new position in Natera in the 3rd quarter worth $57,000. QRG Capital Management Inc. lifted its holdings in Natera by 32.7% in the 2nd quarter. QRG Capital Management Inc. now owns 19,488 shares of the medical research company’s stock worth $5,290,000 after buying an additional 4,797 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its position in Natera by 9.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 4,921 shares of the medical research company’s stock valued at $1,336,000 after buying an additional 429 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.